Last reviewed · How we verify
CBD 20 mg
At a glance
| Generic name | CBD 20 mg |
|---|---|
| Also known as | Cannabis |
| Sponsor | University of California, Los Angeles |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Somnolence
- VITAMIN B6 DECREASED
- BLOOD HOMOCYSTEINE INCREASED
- Diarrhoea
- Decreased appetite
- POSTOPERATIVE WOUND INFECTION
- FALL
- URINARY TRACT INFECTION
- Pyrexia
- EXCESSIVE GRANULATION TISSUE
- INCISION SITE ERYTHEMA
- PROCEDURAL SITE REACTION
Key clinical trials
- Evaluation of Smoked THC and CBD in Men and Women (PHASE1)
- A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex (PHASE4)
- Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa (PHASE2)
- Study of Cannabidiol in Sanfilippo Syndrome (PHASE2, PHASE3)
- Evaluation of Oral THC and CBD in Men and Women (PHASE1)
- TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma (PHASE1, PHASE2)
- Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial (PHASE3)
- Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBD 20 mg CI brief — competitive landscape report
- CBD 20 mg updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI